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17-20% of the world’s cows have had bovine mastitis at some point in their lives. 
Mastitis is the inflammation of mammary glands caused by infection, such as by the 
bacterium Escherichia coli. The focus of this thesis research is the immunopotency of 
a novel catanionic surfactant vesicle vaccine for E. coli mastitis that could 
theoretically resemble an ‘artificial pathogen.’ To this end, serum studies analyzing 
antibody titers and immunogenic profiles were conducted.  These studies demonstrate 
that there was no significant increase in total E. coli specific-IgG in vaccinated cows 














 IMMUNOPOTENCY OF A NOVEL CATANIONIC SURFACTANT VESICLE 












Thesis submitted to the Faculty of the Graduate School of the  
University of Maryland, College Park, in partial fulfillment 
of the requirements for the degree of 













Professor Daniel Stein, Chair 
Associate Professor Kevin McIver 










































First, I would like to thank my adviser Dr. Daniel Stein. Words can’t express how 
your guidance and mentorship have changed the direction of my career and my life.  
Thanks to your full support, I’m headed towards the career path that I’ve always 
dreamed of and the school I’ve always dreamed of attending. Your kindness, 
patience, and love of teaching have helped me develop as a student and as a scientist.  
 
I would like to thank my committee members Dr. Kevin McIver and Dr. Kenneth 
Frauwirth for their comments, feedback, and insights in regards to my thesis as well 
as for all the wonderful experiences I’ve had as a student in their graduate classes.  
 
Next, I would like to thank the people I work with every day, my lab mates: Senthil 
Bhoopalan, Nikki Calli, Britney Hardy, Nadia Kadry, Salsawi Kebede, Mandy Mahle, 
Bryana Rivers, Chuka Udeze, and Mark Wang.  It’s a great joy to come to lab every 
day, see your faces, and share jokes and laughs and perspectives. I’ve greatly enjoyed 
your friendships these past two years and will miss you all a lot.  I wish you the very 
best and I have no doubt you will be amazing at whatever you do, wherever life takes 
you on your adventure. And to Nadia and Chuka, thank you so much for checking in, 
listening, and encouraging me these last few weeks as I wrote my thesis.  
 
I would also like to thank Melanie Khanna, Erin Butler, Alpana Kaushiva, Pooja 
Patil, Maansi Vatsan, Mark Gossage, Hameed Khan, Amy King, and Alexander 
Scheltema for many years of friendship and especially for the support you’ve shown 
me these past two years. You’ve been there for me through tears, fears, laughs, and 
smiles. Through everything you’ve encouraged me, believed in me, listened to me, 
and helped me unwind and just have fun sometimes.  
 
Moreover, I would like to thank my wonderful #Terp Crew cohort: Rachel Godbout, 
Joe Kendra, Steve Smith, Bess Dalby, Surya Sundar, Andrew Richardson, Sarah 
Ahlbrand, Michelle Lazzaro, Pravuthra Raman, and Julie Marré. We’ve all had our 
ups-and-down and our own versions of the love-hate relationship with research but 
through it all, we’ve had each other for support, encouragement, and fun. We’ve had 
some pretty amazing times together both in and out of school. We have some great 
memories, pictures, stories, and inside jokes that I don’t think any of us will ever 
forget.  I’m very glad to have shared my graduate school experience and being a part 
of the BISI program with all of you.  Good luck each of you and keep in touch. You’ll 
always be my first grad school family.  
 
Finally, I would like to thank my family: my cousins Anjana and Vinaya, my 
grandparents Venu and Viji, and especially my parents Ramaa and Vasu for their 
unwavering love, support, and encouragement. I wouldn’t be where I am today 




Table of Contents 
 
 
Acknowledgements ....................................................................................................... ii 
 
Table of Contents ......................................................................................................... iii 
 
List of Tables ................................................................................................................ v 
 
List of Figures .............................................................................................................. vi 
 
Chapter 1: Introduction ................................................................................................. 1 
Bovine Milk.............................................................................................................. 1 
Dairy Industry in the Global and Domestic Markets ............................................ 1 
Bovine Milk .......................................................................................................... 2 
Milk composition and regulations ........................................................................ 2 
Pathogenic Contamination .................................................................................... 4 
Bovine Mastitis ........................................................................................................ 4 
Etiological Agents ................................................................................................. 5 
Signs and symptoms ............................................................................................. 6 
Management, treatment, and control .................................................................... 8 
Significance........................................................................................................... 8 
E. coli Mastitis ......................................................................................................... 9 
E. coli and E. coli strain P4 ................................................................................... 9 
Virulence factors ................................................................................................. 10 
The Mammary Gland and E. coli Pathogenesis ................................................. 14 
Anatomy of the Mammary Gland ....................................................................... 14 
E. coli Pathogenesis ............................................................................................ 15 
Vaccines for E. coli mastitis ................................................................................. 18 
Catanionic surfactant vesicles .............................................................................. 21 
Thesis focus ............................................................................................................ 25 
Hypothesis........................................................................................................... 26 
Specific Aim 1 .................................................................................................... 26 






Chapter 2: Materials and Methods .............................................................................. 27 
Preparation of catanionic surfactant vesicle vaccine ......................................... 27 
Preliminary in vivo vaccine study ....................................................................... 27 
Growth and maintenance of bacterial strains .................................................... 29 
Preparation of Outer Membrane, Inner Membrane, and Cytoplasmic 
Fractions ................................................................................................................ 32 
Collection of bacterial cells after growth ............................................................ 32 
Induction of spheroblast formation ..................................................................... 32 
Isolation of cytoplasmic/inner membrane and outer membrane proteins ........... 33 
Preparation of whole-cell protein fractions ........................................................ 33 
SDS-PAGE/western blot procedures................................................................... 34 
Preparation of protein fractions for SDS-PAGE ................................................. 34 
Separation of protein fractions by SDS-PAGE ................................................... 34 
Silver stain protocol ............................................................................................ 34 
Immunoblotting protocol .................................................................................... 35 
ELISA procedures ................................................................................................ 36 
ELISA plate setup ............................................................................................... 36 
Antibodies ........................................................................................................... 37 
ELISA readings ................................................................................................... 38 
 
Chapter 3: Results ....................................................................................................... 39 
Verification of strain phenotypes ........................................................................ 39 
Determination of pre--vaccination and post-vaccination antibody titers ........ 40 
Identification of potential vaccine antigens ........................................................ 43 
 
Chapter 4: Discussion ................................................................................................. 49 
 














List of Tables 
 
 
Table 1. The two classifications of bovine mastitis. 
Table 2. Vaccination schedule. 
Table 3. Bacterial strains used in this study.  
Table 4. Media used in this study.  
Table 5. Buffers and reagents used in this study. 
Table 6. ELISA setup.  
Table 7. Antibodies used in this study. 
Table 8. Absorbance measurements pre- and post-vaccination. 






 List of Figures 
Figure 1. Percent of cows by health problems.  
Figure 2. Selected E. coli virulence factors. 
Figure 3. E. coli LPS. 
Figure 4. Bovine mammary gland.   
Figure 5. General structure of a catanionic surfactant vesicle. 
Figure 6. Putative outer membrane surface of catanionic surfactant vesicle vaccine. 
Figure 7. Gel loading pattern and silver stain/immunoblotting workup. 
Figure 8. Verification of strain phenotypes.  
Figure 9. Representative ELISA plate.  
Figure 10. P4-specific IgG antibodies in Cow 3643 pre- and post-vaccination sera. 
Figure 11. P4-specific IgG antibodies in Cow 3629 pre- and post-vaccination sera. 
Figure 12. P4-specific IgG antibodies in Cow 3635 pre- and post-vaccination sera. 
Figure 13. Immunogenic profile for Cow 3643. 






List of Abbreviations 
 
APC: antigen presenting cell 
BM: bovine mastitis 
CDC: U.S. Centers for Disease Control and Prevention 
CIM: cytoplasmic/inner membrane protein fraction 
CNS: Coagulase-negative staphylococci 
CO2: carbon dioxide  
CTAT: cetyltrimethylammonium tosylate 
DAEC: diffusely adherent E. coli 
E. coli: Escherichia coli 
EAEC: enteroaggregative E. coli 
EDTA: ethylenediaminetetraacetic acid 
EHEC: enterohaemorrhagic E. coli 
EIEC: enteroinvasive E. coli 
ELISA: Enzyme-linked immunosorbent assay  
EPEC: enteropathogenic E. coli 
ETEC: enterotoxigenic E. coli 
FAO: Food and Agricultural Office of the United Nations 








IgG: immunoglobulin G 
IL-1: interleukin 1 
IL-6: interleukin 6 
IL-8: interleukin 8 
kD: kiloDalton  
Kdo: 3-deoxy-D-manno-octulosonic acid 
KM: Kaleidoscope Marker 
LB: Luria Broth 
LBP: lipopolysaccharide binding protein 
LPS: lipopolysaccharide 
MAC: membrane attack complex 
Mb: megabase 
mCD14R: membrane-bound Cluster of Differentiation 14 receptor  
mg: milligram 
ml: milliliter 
MPEC: mammary pathogenic E. coli 
NASDA: National Association of State Development Agencies 
nm: nanometer 
O.D.: optical density  
OM: outer membrane protein fraction 
PO: post-vaccination 
PR: pre-vaccination 




rpm: rotations per minute 
RT: room temperature 
SCC: somatic cell count 
SDBS: sodium dodecylbenzenesulfonate  
SDS: sodium dodecyl sulfate 
SDS-PAGE: sodium dodecyl sulfate- polyacrylamide gel electrophoresis 
sec: second  
spp.: species  
TLR-4: Toll-like Receptor 4 
TMB: 3, 3′, 5, 5′-tetramethylbenzidine 
TNF-α: Tumor Necrosis Factor α 
TP: total protein fraction 
UD: undiluted 










Chapter 1: Introduction 
 
Bovine Milk  
Dairy Industry in the Global and Domestic Markets 
The dairy industry is a major player in global and domestic markets.  In 2008, a study 
conducted by the Food and Agriculture Organization of the United Nations (FAO) 
analyzing global milk production in 2007 determined that India, the United States, 
China, Pakistan, and Brazil were the top 5 milk-producing countries that year.1 This 
calculation took cow, buffalo, goat, sheep, and camel milk into consideration, but also 
specified that milk derived from cattle represents 83% of the world’s milk.1 The same 
study concluded that between 2002 and 2007 world milk production increased 13% to 
697 million tons.1 
 
 As of 2014, milk production in the United States is projected to reach 93.6 million 
tons.2 Currently, the United States ranks as the third-highest dairy exporter in the 
world, following New Zealand and the European Union.2 In fact, the United States 
Department of Agriculture (USDA) states that for fiscal year 2013 the US dairy 
industry reported exports worth a recording-breaking $6.1 billion.3 Domestically, the 
US dairy industry is responsible for $140 billion in economic output, $29 billion in 
household earnings, and more than  900,000 jobs.4 Clearly, the US dairy industry has 





Bovine Milk  
As defined by FAO, milk is "the normal mammary secretion of milking animals 
without either addition to it or extraction from it, intended for consumption as liquid 
milk or for further processing." 5 Liquid milk ranks as one of the most identifiable 
products of the dairy industry alongside powdered milk, cream, cheese, and butter. 2 
Last year, the US dairy industry produced 201,218 million pounds of liquid milk 
(USDA- National Agricultural Statistics Service). 6, 7    
 
Milk composition and regulations  
Liquid milk comprises of approximately 88% water, 3-4% fat, 3.5% protein, and 5% 
lactose.8 Cows’ milk contains over 400 different fatty acids, which derive from feed 
and microbial activity in the cow’s rumen.9 Fatty acids components include 
conjugated linoleic acid and vaccenic acid, which contains trace elements of natural 
trans-fatty acids that are unique to ruminants.10 The major proteins found in cows’ 
milk are casein and whey.  Casein (asi-> as2, β-casein, and κ-casein) constitute 78% 
of total milk protein.10 Whey constitutes the other 17% of milk protein and includes 
β-lactoglobulin, α lactalbumin, serum albumin, immunoglobulins (Ig), 
glycomacropeptides, lactoferrin, insulin-like growth factor (IGF), and the 
lactoperoxidase system.10 The major carbohydrate component of milk is lactose, a 
disaccharide made of glucose and galactose.10 Given its physiochemical 
characteristics, milk is a popular source of nutrition for cows and humans alike. 
 
Strict federal regulations and safety procedures are enforced by agencies like the 




of State Departments of Agriculture (NASDA) to ensure safe milk for human 
consumption. Consumable milk must contain no debris, off-flavors, abnormal 
coloring or odors, must be low in bacterial counts, contain little to no chemicals like 
antibiotics or detergents, and must retain normal acidity and composition.8 As milk is 
a natural growth medium for microbes, spoilage by organisms in milk and 
transmission of food-borne pathogens 11 are safety concerns that are largely addressed 
by pasteurization. Pioneered by the microbiologist Louis Pasteur, pasteurization 
remains the gold-standard in maintaining milk safety in the US and abroad.  
 
Milk can never be completely sterile once it leaves the udders.12   Pasteurization is a 
process that decontaminates but does not completely sterilize milk, as it reduces the 
number of viable pathogens in milk but does not necessarily kill them all. 12 This 
process reduces the number of milk-borne microbes, yeasts, and molds and extends 
shelf life. 8 Pasteurization techniques include holding vat pasteurization, flash 
pasteurization, and ultra-high temperature pasteurization.12 In the US, each state has 
the authority to regulate pasteurization 12 though there are overarching federal 
agencies like the FDA, USDA, and the US Centers for Disease Control and 
Prevention (CDC) that also monitor milk safety.  According to the 2011 revision of 
the FDA’s Pasteurized Milk Ordinance, it is imperative that milk does “not contain 
levels of deleterious substances, harmful pathogenic organisms, or other toxic 
substances which are secreted in the milk at any level, which may be deleterious to 





Pathogenic Contamination  
Pasteurization helps reduce milk-borne pathogens. These pathogens include human-
derived Streptococcus pyogenes and Salmonella typhi and bovine-derived Brucella 
abortus, Mycobacterium bovis, Listeria monocytogenes, Salmonella species (spp.), 
Campylobacter spp., and Escherichia coli (E. coli) O157:H7. 12, 14 When produced 
and stored in healthy udders, milk is sterile. 12, 15 however, upon exiting the udders, 
milk becomes contaminated by commensal or pathogenic microbes of the udder or 
teat canal, by fecal contamination of the udders, by contamination of milking 
equipment, or by commensal or pathogenic microbes belonging to human milk-
handlers. 12, 15, 16 Of specific relevance to this study is the contamination of milk 
caused by infections of the udders. 16 
 
Bovine Mastitis  
Mastitis is the inflammation of the mammary glands caused by infection.17 Of the 
estimated 250 million dairy cows in the world18, 17-20% have had mastitis at some 
point in their lives.19  In 2007, the disease ranked first among health problems found 
in cows (Figure 1). 20 Over 135 pathogenic species can cause bovine mastitis (BM), 
including bacteria and fungi. 21 BM can be classified as subclinical or clinical and 
contagious or environmental.  BM causes changes in composition and 
physiochemical characteristics 19 that render mastitic milk unsuitable for human 







Figure 1. Percent of cows by health problems. Data was collected related to prevalence of cow health 
problems in the year 2007 published in a National Animal Health Monitoring System study in 2010.  
This figure was constructed based on statistics provided in that document. 20 
 
 Etiological Agents 
Mastitis can be caused by bacterial pathogens. These bacterial pathogens can be 
contagious or environmental (Table 1). 22 Contagious pathogens are those that live on 
mammary gland epithelia and teat lesions as well as on milking machines, milkers’ 
hands, fomites, and sponges. 21 These species include S. aureus, S. agalactiae, 
mycoplasmas and M. bovis.21,22  Contagious pathogens can be transmitted between 
cows or even between quarters during milk. 22, 23 Environmental pathogens derive 
from the cows’ environment and enter the mammary gland by contaminating the 
teat.22  These species include E. coli, S. dysgalactiae, S. uberis, K. pneumonia, and 
Bacillus spp.22 Reservoirs for environmental pathogens include feces, soil, bedding, 
and manure.21  Corynebacterium species and coagulase-negative staphylococcus 




aureus, CNS, and E. coli. 23 Contagious and environmental pathogens can cause 
different signs and symptoms in infected cows. BM can also be described, based on 
signs and symptoms, as either subclinical or clinical (Table 1). Clinical signs of BM 
will be discussed in the next subsection. 
 
Table 1. The Two Classifications of Bovine Mastitis. BM can be identified as  
  environmental/ contagious or subclinical /clinical.24,25 
 
Signs and symptoms 
The severity of a BM case relates to the physical signs and symptoms exhibited by 
the infected cow. BM can be classified as subclinical (asymptomatic) or clinical 
(symptomatic).  In both cases, cows with BM present elevated somatic cell counts 
(SCC). Somatic cells are white blood cells (macrophages, lymphocytes, 
polymorphonuclear cells) and mammary epithelial cells that shed from the infected 
mammary gland into milk upon milking. 26 Elevated SCC can alter the appearance 




somatic cells but at a very low concentration, typically a SCC of <100,000 cells/ml of 
milk. 26 In contrast, mastitic milk typically contains >200,000 cells/ml of milk to an 
upper limit of millions of cells. 26, 27 A SCC of >200,000 cells/ml clearly indicates 
mammary gland inflammation and is synonymous with the diagnosis that the animal 
producing that milk suffers from subclinical or clinical mastitis.  Cows that suffer 
from subclinical mastitis present elevated SCC in milk but no other symptoms. Cows 
that suffer from acute mastitis present elevated SCC in milk and observable 
symptoms. 
  
Observable symptoms can be assessed by considering the state of the cows’ udders, 
the physical appearance of milk collected from cows’, and the cows’ overall health. 
In cases of clinical mastitis, udders frequently appear swollen and hard. 28, 29, 30 
Mastitic milk can appear clotted, thick, serous to yellow colored, flakey, and purulent 
as well as contain blood. 28, 29, 30  Cows with clinical mastitis exhibit high fevers, 
decreased rumen contractions, appetite loss, decreased milk yield, elevated rectal 
temperatures, dullness, diarrhea, depression, and weakness. 28, 29, 30  The observable 
symptoms of clinical mastitis render this form of the disease more easily identifiable.  
 
The consequences clinical mastitis can be severe. Clinical mastitis oftentimes 
becomes systemic, which leads to death. Cows afflicted with clinical mastitis die 
from their condition naturally or are forcibly killed (culled) to prevent further spread 
of the disease. 17, 19, 21, 22, 23, 28, 30, 31 Pregnant cows (periparturient) are especially at 




the dairy industry: economic losses include reduced milk production losses, cost of 
discarded milk, increased cull rates, costs associated with pharmaceutical treatment, 
and increased labor. 32  
 
Management, treatment, and control  
Bovine mastitis is an economically expensive health challenge for the dairy industry. 
Managing, treating, and controlling this disease is a top priority for dairy farmers and 
scientists.  Practices include “establishing good management [of cows] on the farm, 
treating infected animals, and slaughtering chronic cases.” 19 Poor udder hygiene, 
dirty udders, and teats close to the ground are all potential risk factors for mastitis. 31 
In terms of management practices, disinfecting teats with germicidal dipping, 
disinfecting milking equipment before milking, and reducing cow densities per unit 
area all help reduce risk.31,34  Additionally, mastitic cows can be quarantined. Cows 
with chronic mastitis that are especially contagious can be forcibly killed or culled. 
Treatments include novel bacteriophage methods and antibiotics.21   Control methods 
include administrating killed whole-cell vaccines to cows during their dry periods. 21 
Current commercial vaccines for E. coli-associated bovine mastitis will be discussed 
later in this chapter.  
 
Significance 
Bovine mastitis is a disease of public health and economic significance due to its 
impact on human consumption of milk.  Milk is a nutritious source of calcium, 
magnesium, selenium, riboflavin, and vitamin B12.1 However, milk contaminated 




abdominal pain in humans.15 Veterinary drugs and antibiotic residues used to treat 
mastitis can be secreted into milk and can influence milk processing, inhibit acid 
production in starting cultures for cheese, and contribute to poor aging of further 
processed milk products like cheese and butter. 11 The presence of antibiotic residues 
in milk decreases milk quality as well as raises debate regarding excessive antibiotic 
use and the emergence of antibiotic-resistant bacterial species within bovine and 
human populations. 11, 35 Additionally, the presence of somatic cells in milk secretions 
decreases milk and cheese yields as well as influences milk’s nutritional qualities. 30, 
35 Specifically, proteolytic and lipolytic enzymes promote enzymatic breakdown of 
milk protein and fat. 35 Overall, mastitis is estimated to cost $200 per cow affected 
per year, including costs for cow feed, management, treatment, antibiotics, labor, and 
milk. 30 This figure is projected to be a $2 billion loss per year for the dairy industry. 
30 Therefore, controlling the spread of bovine mastitis is in the interest of public 
health and economics. 
 
 
E. coli Mastitis  
E. coli is the most commonly isolated pathogen in cases of environmental (coliform) 
mastitis and frequently causes acute clinical mastitis.23,30 . 
 
E. coli and E. coli strain P4 
E. coli belongs to the Enterobacteriaceae family. 30 It is a Gram-negative, rod shaped, 
lactose fermenting, facultative anaerobe that is commonly found in the 
gastrointestinal (GI) tracts of animals and humans.  Common pathogenic strains 




enterotoxigenic E. coli (ETEC), enteroaggregative E. coli (EAEC), enteroinvasive E. 
coli, (EIEC) and diffusely adherent E. coli (DAEC), which cause GI and urinary tract 
diseases in humans.36   E. coli is classified into serotypes based on shared O 
(lipopolysaccharide) and H (flagellar) antigens. 30, 36 General virulence factors include 
lipopolysaccharide (O antigen), fimbriae, capsules (K antigen), and flagella (H 
antigen). 37 
 
 P4 is a mammary pathogenic E. coli strain (MPEC) responsible for inducing mastitis 
in bovines. 38,28 P4 was first isolated by Andrew John Bramley in 1976 from a clinical 
case.39 P4’s natural reservoirs include the bovine GI tract, soil surroundings in the 
dairy barn, and  bedding.33 P4 utilizes lactose found in milk as a carbon source to 
grow in mammary secretions. 33 Today, P4 is considered a model mastitis-producing 
strain and is used to induce experimental mastitis. 
 
Virulence factors  
P4 was first isolated in 1976, but it was not fully characterized bioinformatically until 
2012 by Blum et al. The Blum group determined that P4 belonged to serotype O32: 
H37. 40 In addition to lipopolysaccharide (LPS), within the 5.2 megabases (Mb) 
genome the following virulence factors were identified: aerobactin siderophores, 
enterobactin siderophores, protein secretion system type II, yidE mediator (for 
hyperadherence), type I fimbriae, type I pili, and curli pili. 40 LPS, flagella, and 





Figure 2. Selected E. coli virulence factors. Adapted from source 81.   
 
 
Lipopolysaccharide (LPS) endotoxin plays a pivotal role in the structure and function 
of Gram-negative outer membranes. 41 The molecule consists of 3 regions: the lipid A 
region, the core polysaccharide region, and the O-polysaccharide region as illustrated 
in Figure 3. 41 The general architecture of a core polysaccharide, made of inner and 
outer cores, and a lipid A portion is highly conserved among Gram-negative species. 
42 More than 180 O-antigen serotypes have been identified and these can be divided 
into the R1, R2, R3, R4, and K-12 groups. 42 The R1 group is commonly found in E. 
coli that colonize humans and bovines.  
 
LPS can be divided into three regions: the O-polysaccharide region, the core 
polysaccharide region, the 3-deoxy-D-manno-octulosonic acid (Kdo) residues, and 
the  lipid A region.42 First, the O-polysaccharide region is made of repeating units of 1 
to 8 glycosyl residues. 42 This region is highly variable due to structural diversity in 
sugars, sequence, chemical linkage, substitution, and ring formations.42 The O-
polysaccharide is the most exterior facing portion of the LPS molecule and as such is 
highly antigenic. 41, 42 The O-polysaccharide also assists in conferring serum 
resistance as it prevents the membrane attack complex (MAC) of the complement 





made of an outer and inner core. The outer core is made of hexose sugars like 
glucose, galactose, N-acetyl galatcosamine, and N-acetylglucosamine. 42 The inner 
core is made of a highly conserved sequence consisting of heptose and Kdo.41,42 E. 
coli LPS’s lipid A region contains acyl chains of C12-C14 length and seems to be 
optimally structured to bind and activate Toll-like Receptor 4 (TLR-4). 42 The lipid A 
moiety is the part of the LPS molecule responsible for its endotoxicity. 41, 42 The LPS 
molecule is amphiphilic, meaning it has a hydrophilic and hydrophobic domain.  The 
lipid A region of the molecule is embedded in the outer membrane while the O-
polysaccharide faces the extracellular milieu. 
  
                     E. coli P4 (R1)                                     E. coli DH5α (K-12) 






LPS is an important factor in determining the severity of E. coli mastitis.43 The 
molecule is found on Gram-negative bacteria and is released upon bacterial lysis. 43 
Once released, LPS enters the teat and udder cistern, where it induces the expression 
of pro-inflammatory cytokines, including Interleukin 6 (IL-6), Interleukin 1 (IL-1), 
Interleukin 8 (IL-8), and Tumor Necrosis Factor (TNF-α). 44 This results in 
leukopenia, leukocytosis, complement activation, macrophage activation, and 
increased vessel permeability, and inflammation.43 Injecting E. coli LPS alone into 
healthy bovine mammary glands is enough to induce mastitis.38,44  LPS is recognized 
by TLR-4 as well as by membrane-bound CD14 receptors (mCD14R)  found on 
macrophages.44 LPS can directly bind mCD14Rs and the binding is facilitated by LPS 
binding protein (LBP), which transfers lipids, promotes LPS disassociation into 
monomers, and catalytically transfers those monomers to mCD14R. 44 LBP 
expression is upregulated by IL-1 and IL-6.44 In an experiment by Yunhe et al 
comparing innate responses elicited by E. coli and S. aureus, it was determined that 
E. coli LPS activated the NFκβ pathway in mammary epithelial cells.45 
  
 
While P4 E. coli is highly virulent in cows, it causes mild or latent mastitis in mice 
that is self-curing. 38 These results suggest that P4 is highly host specific. P4’s niches 
in the bovine mammary gland include stratified epithelial lining, luminal walls, teat 






The Mammary Gland and E. coli Pathogenesis  
Anatomy of the Mammary Gland  
The udders are the milk producing organs of bovines. Each udder is made of 4 
separate mammary glands, each with their own teat end. 46 Mammary gland structure 
is depicted in Figure 4.  Significant features include the teat end, teat cistern, gland 
cistern, alveoli, and ducts.  
 
 
              Figure 4. Bovine mammary gland. Adapted from source 82. 
 
Teats, which allow milk to exit the mammary gland, are made of a teat muscle 
sphincter, a teat canal and a teat cistern. 46 The teat sphincter is the first anatomical 
barrier against mammary infection. 22 The teat sphincter keeps the gland closed 
between milkings and therefore helps prevent bacterial invasion.47 The teat canal  
connects the teat cistern to the teat end. The teat canal contains keratin, a protein 
formed by stratified squamous epithelium. 47 Keratin contains bacteriostatic fatty 
acids like myristic acid, palmitoleic acid, and linoleic acid, a defense against bacterial 
invasion. 47 The teat cistern is a cavity where milk collects before it is expelled 






Milk is synthesized in alveoli by milk-secreting cells. An alveolus is a sac-like 
spherical structure of milk-secreting cells and many alveoli come together to form 
lobules. 48 The overall structure of a lobule resembles the structure of a lung. 48 Milk 
is continuously made and stored in alveoli as well as transported in milk ducts to the 
gland cistern and the teat cistern.48 Alveoli respond to the hormone oxytocin, which 
induces milk to be squeezed out of alveoli into small tubes called ducts, which carry 
milk into the gland cistern. 48 The gland cistern is another collection area for milk, 
which connects directly to the teat cistern, where milk is stored prior to expulsion by 
milking the teat end. 46  
 
E. coli Pathogenesis  
E. coli pathogenesis is a multi-step process, involving colonization, evasion of host 
defense, and host damage. 36 P4 breaches the anatomical defenses of the mammary 
gland and colonizes mammary epithelial cells. Due to the constant presence of lactose 
in milk, which is ubiquitous in the mammary gland, bacteria are able to grow rapidly, 
doubling every 20 minutes. 37, 49 Bacteria colonize epithelial cells in the teat cistern 
and then migrate into the udder cistern. 35 As it grows, P4 releases LPS into the teat 
and udder cisterns. As the bacteria invade epithelial cells along milk-collecting ducts 
and cisterns, it kills milk-secreting cells, whose contents permeate blood vessels and 
attract leukocytes. 30  Blockage of the teat end ultimately ensues and any milk trapped 
inside the gland converts milk-secreting cells into resting cells, resulting in shrinkage 
of alveolis.30  Eventually, E. coli destroy milk-secreting tissues, increasing somatic 





Neutrophils are the first-responders to E. coli infection. In fact, robust neutrophil 
response is the hallmark of E. coli mastitis cases.30 Neutrophils account for 90% of all 
mammary  gland leukocytes.47 Neutrophils migrate from the blood to the site of 
infection, where they are involved in bactericidal killing by phagocytosis and 
respiratory bursts via release of superoxide ions, hypochlorites, and hydrogen 
peroxide.30, 47 Neutrophil recruitment usually occurs 16 hr post-infection and precedes 
increased TNF-α, IL-1β, and C5a production.22 In healthy lactating mammary glands, 
neutrophils are found in a concentration of <105 cells/ml but in mastitic glands 
neutrophil concentrations rise to >106 cells/ml.34 Complement killing is not a very 
effective response to E. coli infection as many strains, like P4, are inherently 
complement-resistant. Serum and milk complement components like C3b and C3bi 
are too low in concentration to contribute significantly to phagocytosis by 
neutrophils.49  
 
After neutrophils, macrophages dominate the immune response.43 Macrophages make 
up the majority of cells in milk and tissue of healthy, lactating mammary glands. 47 
However, macrophages are much less in concentration than neutrophils and have 
fewer Fc receptors than neutrophils.34 Macrophages are involved in bactericidal 
killing by phagocytosis and in antigen processing and presentation by way of their 
MHC class II molecules.47 Macrophages express TLR-4, LBP and mCD14 
receptors.34, 43 TLR-4 recognizes the lipid A portion of LPS.33  mCD14 receptors also 
bind LPS and initiate TNF-α expression.50 Activated macrophages recruit other 




leukotrienes, and cytokines like IL-1, TNF-α, and IL-8, which all enhance the local 
inflammatory response.33, 34 Lymphocytes, cytokines, and chemokines all contribute 
to the local inflammatory response, which is characterized by heat, redness, pain, and 
swelling of the mammary gland.35 The fat and casein found in milk dilute recruited 
immune factors such as neutrophils and macrophages. Neutrophils and macrophages 
can experience ‘phagocytic overload,’ which means instead of ingesting bacterial 
pathogen, they ingest casein micelles and fat globules in milk. This means the 
population of neutrophils and macrophages that would otherwise recognize and 
phagocytize bacteria is reduced. 49 Therefore greater amounts of these factors must be 
continually recruited to infection sites.49 
 
Following macrophage recruitment, adaptive immunity is initiated. Healthy glands 
are mostly populated by CD8+T cells, whereas mastitic glands are mostly populated 
by CD4+ T cells.22 In the mastitic response, CD4+ T cells are activated by antigen-
MHC II complexes on antigen presenting cells (APCs).47 B cells secrete antibodies 
and irreversible class-switching occurs from IgM to IgG1 and IgG2 populations.33  
IgM, IgG1, and IgG2 populations all play a role in opsonization.33,34  IgM could act as 
an opsonin for to recruit milk neutrophils to clear bacterial cells, however to do so 
IgM must first fix complement and the concentration of complement in milk is very 
low.49 IgG is the predominant phenotype in milk.51  IgG1 is the major isotype in 
healthy milk whereas IgG2 is the major isotype in mastitic milk.47,52 IgG1 is the major 
isotype in healthy milk because in healthy milk, massive neutrophil response is not 




IgG1.49 Bovine neutrophils do express high affinity Fc receptors for IgG2, which is 
why IgG2 is the major isotype in mastitic milk.49 Post infection, the blood-milk barrier 
becomes altered.51 Sloughed epithelial, P4 bacteria, and blood components 
(immunoglobulins, neutrophils, macrophages, and lymphocytes) cross into milk, 
rendering that milk mastitic.47,51  
 
Despite a robust bovine immune response, P4 bacteria have developed ways to evade 
host defenses. Firstly, P4 is inherently complement-resistant.52 Therefore, it can evade 
bactericidal killing by host classical and adaptive complement pathways. 
Additionally, P4 can form biofilms and intracellular microcolonies that adhere to 
mammary alveolar epithelial cells, which may have implications the mediation of 
inflammatory responses as well as the process of microbial invasions.38 P4 is also 
resistant to high concentrations of nitric oxide. 38 In these ways, P4 can evade host 
defenses and establish niches in the mammary glands.  
 
Vaccines for E. coli mastitis  
 
Four vaccines are currently available for coliform mastitis: the J5 Bacterin vaccine, 
the MastiguardTM vaccine, the JVAC® vaccine, and the STARTVAC vaccine. These 
vaccines are administered in the non-lactating stages but their effects tend to wane 
over time. 21 They are based on antigens of E. coli LPS. 21 Research into the J5 
Bacterin, long considered the gold-standard in the field of coliform mastitis control, 
and STARTVAC vaccines will be discussed as there are not many published studies 





The J5 Bacterin vaccine is derived from LPS mutant E. coli strain O111:B4. 53 The J5 
strain is a rough LPS mutant, meaning its LPS does not have an O-side chain but does 
have an intact core.54 J5 has been extensively studied since 1989. In a 1989 study 
González et al showed that in a sample population of 218 vaccinated and 
unvaccinated cows, only 35 (6 vaccinated, 25 unvaccinated) developed clinical 
mastitis.55 E. coli was successfully isolated from 2.5% of the  vaccinated and 12.77% 
of the unvaccinated cows. 55  In this study, the J5 vaccine was prepared by heat-killing 
a 24 hr bacterial culture, resuspending the culture in 0.9% sodium chloride solution, 
and emulsifying the antigen by sonication.55 5 ml of emulsified J5 antigen was mixed 
with 1 ml of Freund’s incomplete adjuvant.55 This emulsion was sonicated once more 
time prior to injection.55  
 
In a 2007 study by Wilson et al no difference was observed in antibody 
concentrations between vaccinated and unvaccinated cows.56 Wilson et al conducted a 
2009 study of J5- Bacterin, hypothesizing that vaccination would increase J5-specific 
antibodies in sera.57 The authors collected sera samples for J5-specific ELISA 
assays.57 They observed that prior to vaccination, there was no difference in titer for 
serum-specific IgM and IgG2 between vaccinates and control cows.57 After 
vaccination and calving, the authors observed an increase in J5-specific IgG1 and 
IgG2 in vaccinate cow sera compared to control sera.57 A 2014 study by Tomita et al 






STARTVAC, manufactured by HIPRA, contains inactivated E. coli J5 and 
inactivated S. aureus SP 140. 58 SP 140 is a S. aureus strain that expresses the slime 
and biofilm forming phenotype. 58 STARTVAC is given in 3 doses of 2 ml: the first 
dose is 45 days before parturition, the second dose 35 days after the first dose, and the 
third dose 62 days after the second dose.58 In a study examining 386 cows (198 
vaccinated and 188 control cows) 7 vaccinated cows and 31 control cows developed 
coliform mastitis.58 11.42% of vaccinated cows produced abnormal milk.58 March et 
al concluded the 2 ml dosage and immunization schedule to be effective. 58 The 
STARTVAC vaccine is marketed to protect against E. coli, S. aureus, and CNS.59   
 
Although there are already 4 commercial vaccines for E. coli mastitis, the market 
could benefit from the addition of a fifth vaccine that is based on catanionic surfactant 
vesicles. All 4 current vaccines must be refrigerated. A catanionic surfactant vesicle 
does not need to be refrigerated. A catanionic surfactant vesicle vaccine 
thermodynamically stable at RT for years. A catanionic surfactant vesicle vaccine can 
be autoclaved or pasteurized and so, a single aliquot can be used for many years. 
Also, a catanionic surfactant vesicle vaccine is prepared with relatively inexpensive 
reagents. Finally, the catanionic surfactant vesicle allows for the incorporation of LPS 
without the risk of molecule’s toxicity harming or killing hosts. Thus, there could be 
demand for a catanionic surfactant vesicle vaccine due to its stability, its potential for 
sterilization, its relatively inexpensive preparation, and its ability to present LPS in a 




Eighty percent of all coliform mastitis cases are caused by E. coli.60 However, 
mastitis-causing E. coli has become resistant to many favored antibiotics like 
ampicillin, streptomycin, tetracycline, and sulfonamides. 60  Therefore, immunization 
against E. coli is an attractive endeavor as the goal of a bovine mastitis vaccine is to 
increase sera levels of IgM and IgG2. 56 Thus, developing new vaccines that can 
confer long-term protective immunity is highly anticipated by dairy farmers and 
scientists.  The purpose of this thesis is to investigate one such new vaccine: the 
catanionic surfactant vesicle vaccine.  
 
 
Catanionic surfactant vesicles  
Catanionic surfactant vesicles are derived from colloidal systems.61 Coined in 1861 
by Thomas Graham, colloids are substances of 1 µm to 1 nm size.61 Colloids were 
characterized by lack of sedimentation under the influence of gravity and low 
diffusion rates.61 Today, colloids are defined as systems in which one substance finely 
disperses into another. 61   
 
There are 3 major classes of colloidal systems: lyophobic, lyophilic, and association 
colloids.61 Lyophobic colloids are made of immiscible components.61 An example of 
a commonly encountered lyophobic colloid is milk, wherein liquid fat droplets are 
dispersed in an aqueous phase.61 Lyophilic colloids are spontaneous, 
thermodynamically stable solutions of solute molecules.61 A major branch of 




lyophilic, are aggregates of amphiphilic molecules.61 Association colloids are 
commonly referred to as surface-active agents or surfactants. 61 
 
Surfactants are organic molecules that can move towards surface interfaces when 
dissolved in solvent at low concentrations. 61 Such interfaces include liquid/liquid, 
solid/liquid, and gas/liquid.61 In the case of surfactants, their amphiphilic nature 
allows them to orient at interfaces in such a way that their lyophobic moiety is 
sequestered from strong solvent interactions while their lyophilic moiety remains in 
solution.61 As water is the most common solvent, surfactants’ lyophobic and lyophilic 
moieties are referred as hydrophilic heads and hydrophobic tails.61  
 
Surfactants can be classified by their head groups into the following classes: 
cationics/anionics, non-ionics, and zwitterionics. 61 A catanionic surfactant is a 
mixture of cationic and anionic surfactants. 61 These oppositely charged surfactants 
spontaneously aggregate, forming thermodynamically-stable vesicles in aqueous 
mixtures. 62 Relevant to this study is the use of the cationic surfactant 
cetyltrimethylammonium tosylate (CTAT) and the anionic surfactant sodium 
dodecylbenzylsulfonate (SDBS) in preparing catanionic surfactant vesicles. These 
molecules are shown in Figure 5A. 
 
Surfactants are known for moving towards surface interfaces and for self-assembling 
in bulk phase. 61, 62 They can be emulsified or even made into detergents. 61 




intermolecular interactions are much stronger than water-tail interactions.61 
Surfactants can aggregate as micelles, liquid crystals, bilayers, microemulsions, 
liposomes, and vesicles.62 Liposomes, known as lipid vesicles, are made of 
phospholipid molecules and are formed by the supramolecular interactions of 2 
hydrophobic tails and 1 hydrophilic head group.62 Advances in colloid and liposome 
research have paved the way for recent studies evaluating the use of surfactant 
vesicles as a drug delivery platform.  
 
 
          
 
 
           
Figure 5. General structure of the catanionic surfactant vesicle vaccine. 
Figures were adapted from sources 72 and 83. 
 
In the early 1960s, A.D. Bangham’s work related to liposomes advanced the field of 
colloid science. Based on his work, liposomes became accepted as a model for 
biological membranes.62  In the 1970s, research was conducted into encapsulating 
liposomes, allowing these structures to be applied toward drug delivery and 
A. Structure of CTAT and SDBS.  




pharmaceutical endeavors. 62 Then, in the 1980s, research into catanionic surfactants 
came to the forefront. The term ‘catanionic’ was first used by Jokela et al63. Kaler et 
al noted the spontaneous formation of catanionic vesicles using three different 
catanionic systems, one of them being the CTAT/SDBS system. 64, 65 Hargreaves and 
Dreamer were the first to characterize catanionic vesicles’ ability to carry molecules. 
62 Since then, many other studies have been undertaken to investigate catanionic 
vesicles’ unique properties, especially investigating their applications as drug delivery 
systems and vaccines (Bramer et al 2006; Bramer et al, 2007; Boudier et al, 2011; 
Gosh et al 2013; Stein et al, 2013; Richard et al 2014; Richard et al, 2014) 66, 65, 
67,68,69,70,71  The DeShong group at the University of Maryland, College Park has 
shown that a surfactant vesicle vaccine prepared from a mixture of CTAT/SDBS (see 
Figure 5B) can elicit antibodies against the LPS molecule of  Francisella tularenesis, 
a Gram-negative coccobacillus and the causative agent of tularemia. 70  
 
Catanionic vesicles have many advantages over liposomes as a vaccine platform.  The 
main advantage is that catanionic vesicles form spontaneously from inexpensive 
reagents and are thermodynamically stable.71, 72, 73 For example, liposomes must be 
made from phospholipids like egg yolk phosphatidylcholine ($177/X) whereas 
catanionic vesicles can be made from less expensive ionic surfactants like SDBS 
($1.10/X).72 Another advantage of  vesicles is that they can be sterilized by 
pasteurization at 65oC or by autoclaving.72 With liposomes, proteins can become 
denatured when incorporated into membranes.72 Catanionic vesicles vaccines can be 




into the membranes of the vesicles, creating an ‘artificial pathogen’ whereby proteins 
may be presented on membrane surfaces in their natural conformations.72  In Gram-
negative infections, such as those caused by F. tularenesis and E. coli, LPS is a potent 
and critical immunostimulatory molecule. The surfactant vesicle vaccine platform 
allows incorporation of LPS without the toxicity associated with the molecule. 
Maintaining the conformation of immunogenic surface proteins as well as decreasing 
the endotoxicity of LPS may help elicit long-term protective immunity. 
 
 
Thesis focus  
The focus of this thesis research is the immunopotency of a novel catanionic 
surfactant vesicle vaccine for E. coli (P4) bovine mastitis. In 2000, a liposomal 
complete core LPS vaccine intended for humans was developed from a LPS cocktail 
of 4 Gram-negative bacteria (E. coli K-12, E. coli R1, Pseudomonas aeruginosa 
PAC 608, and B. fragilis).74 However, to date an E. coli mastitis vaccine that 
incorporates the entire LPS molecule as well as other potential immunogenic surface 
components has not yet been developed.  The catanionic surfactant vesicle is one such 
potential vaccine platform.  
 
As depicted in Figure 6, the outer surface of this vaccine could resemble the outer 
membrane surface of a Gram-negative bacterium with LPS, phospholipids, porins, 
and outer membrane proteins in the outer membrane of the vesicle. The lipid A 
moiety of LPS could incorporate into the inner leaflet of the vesicle’s outer 
membrane. The oligosaccharide and O-antigen moieties could into the outer leaflet of 




which does not readily functionalize in vaccine preparations, can be incorporated.75 
The catanionic surfactant platform provides the potential for immunizing cows 
against whole-cell E. coli P4, thereby potentially providing a means to prevent 





Figure 6. Putative outer membrane surface of the catanionic surfactant vesicle vaccine.  





The bovine mastitis vaccine induces a strong antibody response to antigens found on 
the outer membrane surface of E. coli P4. 
 
Specific Aim 1 




Specific Aim 2  










Chapter 2: Materials and Methods 
 
 
Preparation of catanionic surfactant vesicle vaccine  
The bovine mastitis vaccine was developed based on technology described in U.S. 
Patent 20110165067 (Carbohydrate Functionalized Catanionic Surfactant Vesicles for 
Drug Delivery).75 E. coli strain P4 was grown and collected by centrifugation. 
Centrifugation allowed outer membrane proteins to disassociate from the outer 
membrane but kept the peptidoglycan layer intact.  E. coli was then mixed with 
surfactant reagents. Within 12 hr, vesicles formed spontaneously from mixing the 
anionic surfactant SDBS and the cationic surfactant CTAT in a 7: 3 ratio.75  The 180 
nm vesicles were purified on sepharose columns, quantified, and normalized to 
contain 20 mg of LPS.  
 
Preliminary in vivo vaccine study 
Preliminary in vivo studies were conducted in partnership with the USDA. Three 
pregnant heifers were selected. Heifers are cows that are giving birth (calving) for the 
first time. Heifers were preferred over cows because these animals had never suckled 
claves before. Suckling can cause tissue damage to the udders, thereby creating 
opportunities for microorganisms to invade and infect the mammary gland, inducing 
mastitis. Therefore, unlike cows’ udders, heifers’ udders would have minimal 
exposure to environmental pathogens.  Additionally, heifers were selected because 
cows are at a significantly higher risk of developing mastitis during parturition.34 




effects on gestation and the delivery of calves. All 3 heifers in this study delivered 
healthy calves, suggesting this vaccine is safe for pregnant cows.    
 
Heifers were vaccinated with 50 µl of the whole-cell catanionic surfactant vesicle 
vaccine, 45 days prior to their expected calving date (“d 0”).  Each dose of vaccine 
was normalized to contain 20 mg of LPS.  Heifers were then administered a second 
booster dose approximately 21 days into the study (“d 21”).  During this time, blood 
and milk samples were collected from the animals at regular intervals, following the 
schedule outlined in Table 2. Animals were monitored until 14 days after calving. 
 
Three heifers (3635, 3629, 3643) were vaccinated with the P4 vaccine.  Blood 
samples were collected at regular intervals. Pre-vaccination blood was collected on 
d0. Post-vaccination blood was collected the final day of the study (clv d 14).  Serum 
was isolated from the blood samples by collaboraters at the USDA.  
 




Growth and maintenance of bacterial strains  
Bacterial strains used in this study are shown in Table 3.  Media employed are shown 
Table 4.  E. coli strains P4 and DH5α were grown from glycerol stock on Luria Broth 
(LB) agar plates at 37oC for 16-24 hr.  Strains were confirmed to be P4 and DH5α by 
streaking them onto MacConkey’s agar plates, incubating overnight at 37oC and 
observing the lactose utilization patterns.  P4 ferments lactose and DH5α does not. 
Bacterial strains were maintained by subculturing onto fresh LB agar plates daily and 
used for experimentation within 18-24 hr.  N. gonorrhoeae strain MS11 was grown 
from glycerol stock on GCK agar plates at 37oC with 5% CO2 for 16-24 hr. Strains 
were streaked onto fresh GCK agar plates as needed and used for experimentation 













LB agar                         
 
 
LB agar + Ampicillin 
 
 
LB broth   
 
 
MacConkey’s agar                   
 36g Difco TM GC Medium Base (Becton, Dickson, and Co.) 
5g bacteriological agar (U.S. Biological Co.) 
1L Elix water 
10ml 100X Kellogg’s supplement (5g glutamine, 5g ferric nitrate anhydrous, 
 0.02g thiamine pyrophosphate, 1L Elix water, 400g glucose) 
 
40g LB agar base (U.S. Biological Co.) 
1L Elix water  
 
40g LB agar base (U.S. Biological Co.) 
1L Elix water 
30µg/L ampicillin  
 
40g LB Broth Base (U.S. Biological Co.) 
1L Elix water 
  
17g peptone  
3g proteose peptone  
10g lactose 
5g NaCl 
1.0 mg crystal violet 
3.0mg neutral red 
1.5g bile salt 
13.5g agar 
1L Elix water 
pH 7.1 



















Preparation of Outer Membrane, Inner Membrane, and Cytoplasmic Fractions 
Cytoplasmic/inner/outer membrane protein fractions were obtained using 
lysozyme/EDTA lysis and selective detergent isolation following Method 1 
developed by Thein et al.80 The protocol can be divided into three parts: collection of 
bacterial cells after growth; induction of spheroblast formation; and isolation of 
cytoplasmic/inner membrane and outer membrane proteins.  
 
Collection of bacterial cells after growth  
P4 and DH5α were grown from glycerol stocks in LB broth for 16-24 hr at 37oC in 15 
ml centrifuge tube (VWR International).  Bacterial cultures were grown overnight in 
a rolling drum at 37oC. The next day, 1 ml overnight culture was added to 24 ml of 
LB broth, and the cultures incubated at 37oC, 220 rotations per minute (rpm), until 
O.D600.~0.9. Bacterial cells were collected by centrifugation in a Sorvall RC-53 
Refrigerated Super-speed centrifuge for 10 min at 12,000rpm, 4oC.  The supernatant 
was discarded and the pellet, containing whole cell bacteria, was kept for 
resuspension.   
 
Induction of spheroblast formation 
Pellets were resuspended in 500 µl of Buffer 1 (0.2M Tris-HCl, pH 8.0; 1 M sucrose; 
1 mM EDTA).  The resuspension was transferred to a Beckman Ultra-clear centrifuge 
tube.  Lysozyme (100 µl of a 5mg/ml stock solution dissolved in Elix H2O) was 
added to each centrifuge tube, which was flicked gently. The resuspension was 
incubated at room temperature (RT) for 5 min, and 1.76 ml of Elix H2O added. This 




Following spheroblast formation, 3 ml of Buffer 2 (50 mM Tris-HCl, pH 8.0; 2% 
(w/v) Triton X-100; 10 mM MgCl2) and 30 µl of TURBOTM DNase (Ambion®) were 
added.  The suspension was incubated at RT until it cleared.   
 
Isolation of cytoplasmic/inner membrane and outer membrane proteins 
The suspension was clarified by ultracentrifugation at 26,500 rpm for 30 min, 4oC in 
a SW 55 Ti rotor (Beckman Coulter OptimaTM L-90 K Ultracentrifuge).  The 
supernatant, containing cytoplasmic and inner membrane proteins, was collected and 
stored at -20oC.  The pellet, which contained the outer membrane, was re-suspended 
in 750 µl of Buffer 2 and repelleted by ultracentrifugation at 27,000 rpm for 20 min at 
4oC.  The pellet containing the outer membrane fraction was washed with 500 µl of 
Elix H20 and collected by ultracentrifugation at 27,000rpm for 20 minutes at 4oC.  
The membrane was washed 3 times and the final wash was stored at -20oC.  
 
 
Preparation of whole-cell protein fractions 
Whole-cell protein lysates were prepared for each E. coli strain from culture grown 
for 16-24 hr in LB broth.  The remaining 1ml of overnight culture was concentrated 
using a tabletop centrifuge (eppendorf Centrifuge 5417C) at 10,000rpm for 10 min at 
RT. Pellets were resuspended in 50 µl of Lysing Buffer and stored at -20oC. To all 






SDS-PAGE/western blot procedures  
Aliquots of membrane fractions were analyzed by gel electrophoresis through a 10-
20% SDS-PAGE gel. Half of the gel was silver stained and the other half was 
immunoblotted using Pre-Vaccination and Post-Vaccination sera as primary 
antibodies.  
 
Preparation of protein fractions for SDS-PAGE 
The amount of protein contained in each fraction was determined using a Nanodrop 
(ND-100 Spectrophotometer) by loading 2 µl of protein fraction and measuring the 
absorbance at A280.  A concentration was given in mg/ml and each fraction was then 
normalized to 10 µg of protein: 10 µl samples of each fraction were prepared for 
SDS-PAGE analysis in 1X Lysing Buffer.  
 
Separation of protein fractions by SDS-PAGE 
Prior to loading, samples were boiled at 100oC for 10 min and vortexed for 30 sec.  
Samples were loaded on a 10-20% Criterion Tris-HCl gel (Bio-Rad) in the pattern 
shown in Figure 7.  Experimental samples (10 µl) were loaded alongside 1µl of 
Precision Plus Protein TM Kaleidoscope Standard (Bio-Rad).  The gel was placed in a 
Criterion cell, immersed in 1X Running Buffer, and run at constant current (100 mA) 
on ice for 2-4 hr.  After electrophoresis, the gel was cut and used immediately for 
immunoblotting and silver staining.  
 
Silver stain protocol   
The gel was fixed in Fixing Solution (500 ml) overnight at RT. The next day, the gel 




2 hr. During the wash period, water was changed every 30 min. Silver Stain was 
applied for 15 min at RT. The gel was washed 3 times, 30 min each, with 250 ml of 
Elix. Staining was detected by allowing the gel to soak in developing Solution until 
bands became visible. The gel was given a final water rinse and then imaged using 
the Bio-Rad ChemiDocTM XRS Gel Documentation system and Bio-Rad Quantity 
One ® software. 
 
Figure 7. Gel loading pattern and silver stain/immunoblotting workup. 10 µl of each sample was 
run in the following pattern: Kalediscope Marker (KM), DH5α Total Protein (D-TP), DH5α 
Cytoplasmic/Inner Membrane (D-CIM), DH5α Outer Membrane (D-OM), P4 TP (P-TP), P4 CIM (P-
CIM), P4 OM (P-OM), KM. Empty lanes (blnk) contained 10 µl of 1X Lysing Buffer.  The gel was 
run at constant 100 mA and following electrophoresis, was cut along lane 16. The first gel was used for 
immunoblotting and the second gel was used for silver staining. 
 
 
Immunoblotting protocol  
Immediately following electrophoresis, the gel was transferred in Transfer Buffer to a 




The membrane was blocked overnight at 4oC in Blocking Buffer.  The next day, the 
membrane was cut along lane 9 (Kaleidoscope Marker). The left half was probed with 
pre-vaccination (PR) cow serum and the other half with post-vaccination (PO) cow 
serum.  The membranes were incubated in 10 ml of their respective primary 
antibodies (see Table 7) overnight at 4oC. The next day, the membrane was washed 3 
times in PRST for 15 min and rinsed in Elix H2O 3 times. The membrane was 
blocked again for 1 hr at RT, probed with 50 ml of secondary antibody at RT for 1 hr, 
washed in PRST 6 times, and rinsed in Elix H2O 3 times. The blot was developed 
using 2 ml of the Western Blotting Luminol Reagent system (Santa Cruz 
Biotechnology) at RT for 5 min.  Finally, the blot was imaged using audiography or 
the LAS-3000 Imaging System (FUJIFILM) and quantified using ImageJ software 
(National Institutes of Health). 
 
 
ELISA procedures  
Enzyme-linked immunosorbent assays (ELISAs) were performed on pre- and post-
vaccination sera.  
 
ELISA plate setup  
Control gonorrheal strain MS11 wild-type and experimental coliform strain P4 were 
grown overnight. Bacteria were swabbed from the plate using a Dacron swab and 
resuspended in 4 ml of 1X PRS to a turbidity of 100, as measured with a Klett 
Summerson Photoelectric Colorimeter.  Bacteria (100 µl) was added to 96 well 




Table 6.  Plates were incubated at 37oC for 3 days to allow bacteria to adsorb. The 
experimental controls were a blank control (wells A1-3, E1-3) and two sample 
controls (wells A5-7 and A9-12).  The controls were duplicated in Rows A and D. 
The experimental pre-vaccination samples were triplicated in Rows B, E, and G. The 
experimental post-vaccination samples were triplicated in Rows C, F, and H. 
 




Cow primary antibody solutions were prepared in 2 ml quantities following a 12 two-
fold serial dilution scheme. Dilutions were prepared from 1:100 to 1:102,400.  Cow 




Description  Designation Stock Volume; Dilution in PRST 
Heifers 3643, 3629, 
3635 Pre- and Post-
Vaccination sera 
 





Goat α N. 
gonorrheoae IgG 
bleed 3 antisera 
 
Donkey α goat IgG-
HRP 
  1’ antibody        Immunoblot: 10ml; 1:500 




2’ antibody        Immunoblot: 50ml; 1:50,000 
                          ELISA: 45ml; 1:30,000 
 
 




2’ antibody        Immunoblot: 1ml; 1:10,00 
 
Table 7. Antibodies used in this study.  
 
 
N. gonorrheoae primary antibody (goat α N. gonorrheoae IgG bleed 3 antiserum) was 
prepared in 1 ml quantities and diluted 1:50. N. gonorrheoae secondary antibody 
(donkey α goat IgG-HRP) was prepared in 1 ml quantities and diluted 1:10,000.  
Antibodies were used at RT and stored at -4oC. The antibodies used in this thesis are 












ELISA readings  
Wells were blocked with 250 µl Blocking Buffer for 1 hr at RT. Wells were rinsed 
with PRST 3 times. Wells were probed with primary antibody (50µl) for 1 hr at RT, 
rinsed with PRST 3 times, and dried by aspiration. Wells were probed with secondary 
antibody (70 µl) for 1 hr at RT and rinsed with PRST 6 times. Finally, wells were 
developed with trimethylbenzidine (TMB) (Sigma) (100µl) for 5 min at RT. The KC4 
Plate Reader program was employed to measure absorbance at 645 nm every min for 





Chapter 3: Results 
 
 
Verification of strain phenotypes 
P4 and DH5α E. coli were swabbed on MacConkey’s agar and allowed to grow for 18 
hr. MacConkey’s agar contains lactose as its carbon source. As seen in Figure 8, only 
P4 is able to utilize and ferment lactose, generating an acidic by-product that renders 
the agar on which it grows pink. DH5α is a lactose operon deletion mutant and as 
such cannot utilize the lactose on the MacConkey’s plate as its carbon source. 
Instead, DH5α uses the peptones in the agar, generating ammonia as a by-product, 




Figure 8. Verification of strain phenotypes.  
P4 ferments lactose (pink colonies) and 










Determination of pre--vaccination and post-vaccination antibody titers  
The concentrations of IgG antibodies in sera pre- and post-vaccination were analyzed 
by performing direct ELISAs. Antigen (whole-cell P4) was adsorbed to wells of a 
microtiter plate. Antiserum (PR and PO sera) was diluted 2-fold from 1:100 to 
1:100,240 and probed with a secondary horseradish peroxidase (HRP)-conjugated 
antibody that recognizes bovine IgG molecules. HRP cleavage of the substrate TMB 
forms a blue-colored product, the absorbance of which was measured at O.D. 
645nm.An example of a representative ELISA plate is shown in Figure 9, which 
follows the same setup depicted in Table 6.     
 
 
Figure 9. Representative ELISA plate. 
 
The absorbance readings for PR and PO sera of cows 3643, 3629, and 3635 are given 
in Table 8.  These data are corrected values after the values for the blanks were 




graphs to determine antibody titers. Graphs are shown as follows: Cow 3643 (Figure 



























       Table 8. Absorbance measurements pre-vaccination and post-vaccination. 
 
 
Figure 10. P4-specific IgG antibodies in Cow 3643 pre-and post-vaccination sera. 
  Absorbance measurements at O.D.645 




PR              PO PR          PO PR              PO 
1 0.555 0.451 0.399 0.322 0.558 0.567 
100 0.516 0.567 0.371 0.416 0.490 0.491 
200 0.443 0.507 0.270 0.290 0.415 0.460 
400 0.319 0.323 0.210 0.211 0.285 0.302 
800 0.198 0.181 0.136 0.153 0.176 0.203 
1,600 0.124 0.102 0.088 0.102 0.106 0.103 
3,200 0.063 0.057 0.061 0.065 0.067 0.075 
6,400 0.044 0.034 0.044 0.051 0.042 0.054 
12,800 0.026 0.025 0.036 0.038 0.033 0.039 
25,600 0.022 0.018 0.035 0.031 0.023 0.032 
51,200 0.021 0.023 0.026 0.030 0.027 0.030 






Figure 11. P4-specific IgG antibodies in Cow 3629 pre-and post-vaccination sera. 
 
 








For all 3 cows, background existed in the ranges of dilution factors 12,800 to 
102,240.  Antibody titer is defined as the greatest dilution of antisera that still allows 
for detection. Titer for all 3 cows’ pre-and post-vaccination sera was 6,400. For cow 
3643, detection was observed between absorbance 0.340 to 0.325. For cow 3629, 
detection was observed between absorbance 0.044 to 0.300. Finally, for cow 3635 
detection was observed between absorbance 0.042 to 0.302. Plateaus of saturation 
were observed for all cows from dilution factors 200 to undiluted.  Based on titer, 
conclusions can be made about antibody concentration in sera pre-and post-
vaccination. These conclusions will be discussed in the following chapter. 
 
Matched two-tailed student t-tests were performed on all 3 sets of ELISA data.  The P 
value for cow 3643 was 0.858. The P-value for cow 3629 was 0.728. Finally, the P 
value for cow 3635 was 0.012. The meaning of these P values will be discussed in the 




Identification of potential vaccine antigens  
Immunoblot analyses were conducted to identify potential P4 antigens that had 
incorporated into catanionic surfactant vesicles. Outer membrane proteins were 
thought to have been extracted from P4 E. coli into the outer membrane of the 
catanionic surfactant vesicle vaccine.  It was hypothesized that the vaccine could 





Thus, subfractionation of E. coli cells was conducted to assist in identifying which P4 
antigens incorporated where in the catanionic surfactant vesicle. The following 
fractions were prepared and analyzed: total proteins (TP), cytoplasmic/inner 
membrane proteins (CIM), and outer membrane proteins (OM). E. coli DH5α protein 
fractions were used as controls. E. coli P4 protein fractions were used as experimental 
samples. To aid in identifying potential antigens in the vaccine, immunogenic profiles 
were generated. Each immunogenic profile consists of a silver stain, an immunoblot 
using pre-vaccination and post-vaccination sera as primary antibody, and histograms 
of the distribution by size of protein antigens in each fraction. Histograms, a 
densitometric analysis, relate detection to number of proteins. Profiles are shown for 
cows 3643 (Figure 13) and 3635 (Figure 14).  
 
Cow 3643’s silver stain revealed the presence of lipoproteins, the “blank bands” in 
the gel. The lipid portions of these proteins do not take up silver stain completely. A 
doublet of lipoproteins was observed in the 60 kiloDalton (kD) range in P4 and DH5α 
OM fractions.  CIM proteins were observed from 100 kD and below. CIM proteins 
were strongly seen in the 37 to 10 kD range. A 20 kD band was observed in all 
fractions: TP, CIM, and OM of P4 and DH5α. The relative density of this band was 
calculated across the fractions with the DH5α-TP band as the control. The data 







Lane  Area Percent  
Relative 
Density  
1 221340.9 18.245 1.00 
2 156914 12.934 0.71 
3 155296 12.801 0.70 
4 155655.3 12.83 0.70 
5 156293 12.883 0.71 
6 156765 12.922 0.71 
Table 9. Relative density of 20 kD band across all protein fractions (Silver Stain, Cow 3643). 
 
Shown in Figure 13, an immunogenic profile for Cow 3643 was generated. The 
immunoblot showed a prominent band in the 75 kD range in all DH5α and P4 
fractions but the CIM fraction. A band was observed in the 200 kD range in all 
fractions except in the OM fractions. A band in the 150 kD range was strongly 
observed in the P4-OM fraction by pre-vaccination probing. This ~150kD band was 
not strongly observed in the P4-OM fraction by post-vaccination sera probing. Again, 
in the immunoblot a 20 kD band was observed in all fractions. Normalization of the 
200 kD, 150 kD, and 75 kD bands relative to the 20 kD was not pursued due to the 
saturation already present in the immunoblot. Histogram analysis of the 
immunoblotted protein fractions showed protein detection across pre-and post-
vaccination sera did not differ significantly, except for in the P4 OM fractions. The 
histograms reveal a slight shift in peak distribution towards higher molecular weight 
proteins in the post-vaccination serum probing of P4 OM fractions. Specifically, the 
mode for pre-vaccination serum detection was 52 and the mode for post-vaccination 


















        










B  Immunoblot of Pre-and Post-Vaccination  












Shown in Figure 14, an immunogenic profile for Cow 3635 was generated. A silver 
stain of cow 3635 protein fractions was performed. Again, a band around 75 kD was 
observed in all fractions. A strong doublet lipoprotein band was observed in the TP 
fractions in the 50 to 37 kD range. A prominent band was observed in all fractions at 
20 kD as was seen in the previous silver stain. Bands in the 200 kD range were also 
observed in TP and OM fractions. Looking at the immunoblot, a prominent 200 kD 
band was observed in P4-TP and-OM fractions pre-and post-vaccination. A 75 kD 
band was observed in all fractions but CIM. CIM bands were observed only in the 25 
to 10 kD range on the immunoblot. By histogram analysis, the only significant 
differences in detection were between detection of P4 OM fractions pre-and post-
vaccination. Pre-vaccination serum detected a high number of protein counts in the 
30-100 peak range. Post-vaccination serum detected a high number of protein counts 
in the 200-230 peak ranges.  Specifically, the mode for pre-vaccination serum 





















    









B  Immunoblot of Pre-and Post-Vaccination 








Chapter 4: Discussion 
 
The goal of this project was to investigate the immunopotency of a catanionic 
surfactant vesicles as a potential vaccine platform. This project focused on 
investigating if a catanionic surfactant vesicle vaccine could elicit antibody response 
against E. coli, a causative agent of bovine mastitis. Specifically, it was hypothesized 
that the vaccine could elicit strong antibody response against E. coli outer membrane 
antigens. It was predicted that data generated may offer insight into whether the 
vaccine could elicit protective immunity against E. coli. The goals of this particular 
vaccine were 1) determining if the vaccine formulation decreased the inherent 
toxicity of incorporating the lipid A portion of LPS and 2) determining what, if any, 
effect the vaccine formulation had on antibody production in cow serum.  
 
Based on these goals, success could be framed in the context of survival of animals 
that received the vaccine. The 3 heifers that were vaccinated in the study all survived 
vaccination and were alive at the conclusion of clv d 14. Additionally, success could 
be framed in the context of the delivery of healthy offspring. All heifers in this study 








Another context by which success could be defined is by the vaccine formulation’s 
effects on bovine antibody production in serum. At the very least, success could be 
thought of as the vaccine’s ability to generate an antibody response. To validate this 
perspective, serum studies were performed. These studies were ELISAs and 
immunoblots.   
 
A vaccine was developed using E. coli as the bacterium causes 80% of all coliform 
mastitis cases.60 Moreover, E. coli was chosen over other causative agents like S. 
aureus as E. coli is a Gram-negative bacterium. Previous published data from the 
DeShong group70 and unpublished data from the Stein group69 have demonstrated the 
suitability of a catanionic surfactant vesicle platform in eliciting antibody against 
LPS/LOS.  This thesis utilized DH5α and P4 E. coli as the control and experimental 
coliform strains. 
 
DH5α was selected as the control coliform strain. DH5α shares structural and 
antigenic characteristics with P4. However as a laboratory strain, DH5α has been 
genetically modified and no longer expresses some characteristics that contribute 
towards virulence such as lactose utilization79 and an O-antigen.42 This strain belongs 
to the K-12 O-antigen serotype 42, meaning it does not express O-antigen, rendering 
bacteria sterically susceptible to complement-mediated killing (serum sensitivity). 
Additionally, the lack of O-antigen renders bacteria less antigenic than R-1 strains 
like P4. DH5α can be considered an avirulent E. coli strain whereas P4 is a highly 




in cases of clinical mastitis. 39, 78 and is used to induce experimental mastitis. 
Responses to DH5α were to be compared with responses to P4 in the hopes that 
surface antigens unique to P4 could be discerned. Overlap in responses could be 
attributed to shared structural features and the response to DH5α could be ‘subtracted 
out,’ giving further insight into vaccine-induced P4-specfic responses.  
 
The ELISA experiments, under the conditions described in this thesis, suggest there 
was no significant difference in bovine IgG concentration after vaccination. For 
example, significant difference is defined as P<0.01. P values for each cow’s ELISA 
readings are as follows: Cow 3643 (P=0.858), Cow 3629 (P= 0.728), and Cow 3635 
(0.012). Based on the parameters of the experiment conducted, it could concluded 
that 1) there was no observable difference in IgG concentrations after vaccination and 
2) perhaps the vaccine formulation was unable to elicit an IgG response. These 
observations are in stark contrast to Wilson et al’s J5 Bacterin vaccine study, which 
showed increase in J5-specific IgG post-vaccination.57 
 
On the other hand, the argument can be made that differences in IgG concentration 
may be obscured by a high background of non-specific binding. This could be 
concluded because whole-cell P4 reacted strongly to Neisserial primary and 
secondary antibody, as observed qualitatively by comparing intensity of blue color 
development between P4 and MS11 control wells. Blue color was equally intense 
between P4 and MS11 wells. Ideally, P4 would have little to no specificity for 




E. coli response to Neisserial antibodies may have been observed because of 
improper blocking of wells. Perhaps wells could have been blocked overnight at 4oC 
instead of for 1 hr at RT. Another explanation for non-specific binding could be the 
choice of 5% BSA solution as the blocking buffer. Cows naturally produce BSA in 
their sera Blocking with BSA may not then have been the most choice, given that this 
protein is already highly prevalent in bovine sera and given that in these experiments 
bovine sera were used as primary antibodies. In these studies BSA, casein, or 
powdered milk should not be used as blocking reagents. These reagents could interact 
with antibodies present in bovine sera. An alternative experiment could be to repeat 
the ELISA procedures using a regent like fish gelatin as a blocking buffer. 
 
The use of additional positive and negative controls could help troubleshoot the 
ELISA studies. Since P4 belongs to E. coli serotype O32: H37, 40 antibodies for O32 
O-antigen or H37 flagellar antigen could be used as positive controls to probe 
specifically for P4. Theoretically, only wells with P4 should have TMB development.  
Since these antigens are highly specific for P4, wells with MS11 should have no 
TMB detection.  One negative control could be probing bovine antisera with bovine 
secondary antibody. As these wells would contain no bacteria, theoretically antisera 
would not bind the well, preventing the binding of secondary antibody and the 
cleavage of TMB substrate. Little to no TMB should be detected in a well with only 
bovine antisera and bovine secondary antibody. Similarly, to assess non-specificity 
another negative control could be probing MS11 with bovine antisera and bovine 




at any point in their lives and therefore should not produce antibodies against this 
bacterial species. Ideally, little to no TMB should be detected in wells with Neisseria, 
bovine antisera, and bovine secondary antibody. In the future, ELISA studies could 
be repeated with these positive and negative controls. ELISAs could be optimized to 
reduce the high background of non-specific binding and perhaps in this new context, 
differences between IgG concentrations pre- and post-vaccination could be seen. 
 
Based on the immunogenic profiles generated in this thesis, it could be concluded that 
post-vaccination, antibodies were produced to high molecular proteins found mostly 
in P4’s outer membrane. For example, there was an antibody response to a high-
molecular weight protein on P4’s OM surface in the post-vaccination serum of one 
cow (Cow 3635). The presence of that 200 kD band may warrant further study. To 
better identify that protein, bands could be excised from the gel, analyzed, and 
structurally characterized by mass spectrophotometry. One interpretation of the data 
could be that vaccination may elicit antibodies to P4 OM antigens and that in this 
way, the vaccine may potentially hold promise as an alternative commercial 
therapeutic for decreasing symptoms of clinical mastitis and improving the quality of 
milk obtained from mastitic cows.  
 
However, another interpretation of the immunogenic profiles generated in this thesis 
is that high background response to common DH5α and P4 antigens obscures P4-
specific antibody binding. This could be concluded from comparing histogram 




specific bovine serum antibody response to DH5α proteins.  Non-specific antibody 
response to DH5α proteins could be minimized in future studies by conducting an 
antibody absorption experiment. Bovine antisera could be absorbed with DH5α whole 
cell antigen to eliminate non-specific binding. Immunoblotting could be repeated 
using absorbed pre-and post-vaccination primary antibodies. Immunoblots probed 
with absorbed antisera should theoretically demonstrate P4-specific binding.  
Histogram analyses of these immunoblots should reveal little to no detection of 
protein bands in the DH5α fractions and detection of some unique protein bands in 
the P4 fractions. These changes could be applied to future immunoblot studies and 
perhaps in these studies, detection of P4-specific antigens could be seen.   
 
Data generated from this study can be compared to what is known about current 
vaccines for bovine mastitis. The well-studied vaccine available is J5 Bacterin. In 
previous studies related to J5 Bacterin, Wilson et al observed no differences in 
antibody concentrations prior to vaccination between vaccinated and unvaccinated 
cows. 56 Another study showed vaccination increased J5-specific IgG2 antibodies.57 In 
this thesis study, P4-specific IgG antibodies remained relatively unchanged. But 
perhaps, IgG2 and IgG1 populations differed pre-and post-vaccination. Knowing this, 
further ELISA studies could be done to determine whether vaccination promoted P4-
specific IgG2 production while reducing IgG1 production. Secondary antibodies that 
distinguish between the two IgG isotypes could be used in these studies. Additionally, 
perhaps the vaccine was unable to elicit class-switching from IgM to IgG. If that is 




determine the validity of this hypothesis, ELISAs could be conducted specifically for 
bovine IgM instead of IgG.  
 
A major limitation of this study could be the 3 heifers chosen for the preliminary trial.  
Under the parameters of this thesis, even if these animals had exposure to P4 E. coli 
prior to the study this may not have been observed with the high background of non-
specific binding. Optimizing the ELISA and immunoblot experiments to minimize 
non-specific binding would help in determining what effect exposure to E. coli prior 
to vaccination has on the data. Theoretically, vaccines should elicit highly specific 
and robust responses despite prior exposure.  
 
Overall, this study could benefit from further optimization to reduce the non-specific 
binding of bovine sera antibodies. At this time, given the parameters of this thesis, 
conclusive statements regarding the immunopotency of the catanionic surfactant 
vesicle as a vaccine platform cannot be made. Nonetheless, catanionic surfactant 
vesicles could hold potential as a vaccine platform as they are relatively inexpensive 
to prepare, can be stored long-term at room temperature, can be autoclaved and 
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